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response to cellular antigens by peripheral
lymphocytes from normal and lung cancer
patients in serum free medium in vitro
(Aaskov and Anthony, Biomedicine, 1973,
19, 369). In common with results published
for the one-stage MMI test, occasional
stimulation of migration has been noted
in this assay. Because of the problem of
assaying migration inhibition factor (MIF)
in the presence of stimulatory material,
attempts have been made to identify the
materials responsible for this stimulation.
Sephadex chromatography yielded an
MIF (mol. wt 20-30,000) and a chemotactic
factor (protein, mol. wt approximately
12,500) from supernates of antigenically
stimulated lymphocytes. The chemotactic
material had no stimulatory effect on
macrophage migration. Stimulation of mi-
gration was observed in fractions from
2 peaks (mol. wt >150,000 and mol. wt
60-70,000). Assay after isoelectric focusing
has shown this to be due to Hb and IgG.
The stimulatory effect of these substances
at certain concentrations has been confirmed.
SPLEEN SIZE IN PATIENTS WITH
BREAST CANCER. J. G. ROBERTS, M.
WISBEY, K. G. LEACH and M. BAUM, Depart-
ments of Surgery and Medical Physics,
Welsh National School of Medicine and the
University Hospital of Wales.
Gamma camera images of the spleen
obtained following the intravenous injection
of heat damaged, autologous, 99Tcm labelled
red cells provide a means of estimating
spleen size in patients.
A new method of calculating spleen size
has been validated in 10 patients. The
computed weight correlated well with the
exsanguinated weight of the excised spleens
(r = 0 9894) wNith 9500 confidence limits
of less than 50 g. This technique has been
applied to 40 patients with breast cancer
and 5 controls. The cancer patients had
significantly larger spleens (P < 0.05) and
spleen size varied with clinicopathological
stage. In 10 patients spleen size has been
estimated at primary treatment and some
6 months later. All patients except one
showed a reduction in spleen size (P < 0 01).
These results suggest that in man, as in
experimental animals, splenomegaly occurs
as a component of the host response to
cancer.
IMMUNITY IN PATIENTS WITH
BREAST CANCER. A. J. COCHRAN, R. M.
MACKIE, C. E. Ross, R. M. GRANT and
D. E. HOYLE, University Department of
Pathology, Western Infirmary, Glasgow.
We have examined tumour directed
immunity and nonspecific immunological
activities in 200 patients with breast car-
cinoma. Techniques employed included skin
testing with recall antigens, the leucocyte
migration technique (LMT), mitogen induced
transformation, an immune adherence tech-
nique, immunoglobulin and complement
assays and T and B cell quantification.
The main findings are: (1) A majority
of breast cancer patients (54%0) showed
evidence of sensitization to tumour derived
materials; (2) sensitization is rare in control
donors (15%). This is true of normal
donors, patients with simple breast disease
and those with other malignancies; (3) in-
hibition of migration was similarly frequent
with homologous (53o%) and autologous
(56%) combinations of antigens and leuco-
cytes; (4) sensitization is less commonly
demonstrable in patients with advanced
disease (27%0); (5) patients with local recur-
rences were as frequently reactive as those
with primary tumours only (60%); (6)
extracts of mastopathic breasts only rarely
inhibited the migration ofleucocytes whether
from cancer patients (210%) or controls
(170%); (7) there is some evidence that
non-cancerous tissues in cancerous breasts
may possess tumour-like antigens. The sig-
nificance of these results, obtained mainly
with the LMT, can be assessed by relating
them to results obtained by the other
techniques.
THE RELATIONSHIP BETWEEN
PROGNOSIS AND LYMPHOCYTE
RESPONSE TO PHA IN BREAST
CANCER. P. M. BOLTON, R. H. WHITE-
HEAD, R. G. NEWCOMBE, S. L. JAMES and
L. E. HUGHES, Departments of Surgery and
Medical Statistics, Welslh National School of
Medicine, Cardiff.
Studies of lymphocyte response to PHA
in cancer patients have shown variable
results, probably due to methodological
differences. We have used a microtest
method with 3 PHA dose levels (0*3 ,ug/ml,
0*8 ,ug/ml and 40) ,ug/ml) to study the
lymphocyte response in 119) patients witl
breast disease. These patients wi-ere classi-